Menlo Therapeutics Inc (MNLO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Menlo Therapeutics Inc (MNLO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8270
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Menlo Therapeutics Inc (Menlo Therapeutics) formerly Tigercat Pharma Inc, is a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions such as psoriasis and prurigo nodularis, and for refractory chronic cough. Its pipeline product candidate serlopitant, is a small molecule, highly selective NK1-R antagonist which reduces pruritus and refractory chronic cough symptoms. The company has licensing opportunities for development and commercialization of its pipeline product in all markets other than Japan. Menlo Therapeutics is headquartered in Redwood City, California, the US.

Menlo Therapeutics Inc (MNLO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Menlo Therapeutics Raises USD50 Million in Series C Financing 10
Tigercat Pharma Raises Funds Through Venture Financing 12
Tigercat Pharma Raises US$0.5 Million In Venture Financing 13
Menlo Therapeutics Raises USD14.5 Million in Series A Financing 14
Licensing Agreements 15
Menlo Therapeutics Enters into Licensing Agreement with Merck 15
Equity Offering 16
Menlo Therapeutics Raises USD137 Million in IPO 16
Menlo Therapeutics Raises USD45 Million in Private Placement of Preferred Stock 18
Menlo Therapeutics Inc – Key Competitors 19
Menlo Therapeutics Inc – Key Employees 20
Menlo Therapeutics Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
May 09, 2018: Menlo Therapeutics Reports First Quarter 2018 Financial Results 22
Mar 28, 2018: Menlo Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 24
Corporate Communications 26
Jan 05, 2017: Menlo Therapeutics announces management changes 26
Product News 27
10/17/2017: Menlo Therapeutics Expands its Management Team 27
01/05/2017: Menlo Therapeutics Recruits Experienced Management Team and Board Leadership to Accelerate Development of Serlopitant for Treatment of Pruritus 28
Clinical Trials 29
Apr 08, 2018: Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis 29
Feb 20, 2018: Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of Dermatology 30
Nov 21, 2017: Menlo Therapeutics Begins Phase 2 Clinical Trial for Pruritus Associated with Psoriasis 31
Oct 26, 2017: Menlo Therapeutics Initiates Enrollment in Phase 2 Clinical Trial with Serlopitant for Refractory Chronic Cough 32
Sep 18, 2017: Serlopitant Pruritus Reduction Results from Two Phase 2 Studies Presented at the 26th European Academy of Dermatology and Venereology 33
Mar 08, 2017: Menlo Therapeutics Announces Successful Pruritus Reduction Results from Phase 2 Serlopitant Trial (TCP-102) in 127 Subjects With Prurigo Nodularis 34
Jan 06, 2017: Menlo Therapeutics Starts Enrollment in Two Phase 2 Studies for Pruritus Associated with Atopic Dermatitis and Pruritus Following Burn Injury 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Menlo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Menlo Therapeutics Raises USD50 Million in Series C Financing 10
Tigercat Pharma Raises Funds Through Venture Financing 12
Tigercat Pharma Raises US$0.5 Million In Venture Financing 13
Menlo Therapeutics Raises USD14.5 Million in Series A Financing 14
Menlo Therapeutics Enters into Licensing Agreement with Merck 15
Menlo Therapeutics Raises USD137 Million in IPO 16
Menlo Therapeutics Raises USD45 Million in Private Placement of Preferred Stock 18
Menlo Therapeutics Inc, Key Competitors 19
Menlo Therapeutics Inc, Key Employees 20

List of Figures
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Menlo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Menlo Therapeutics Inc (MNLO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aibel AS:企業の戦略的SWOT分析
    Aibel AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Transocean Ltd.:企業の戦略・SWOT・財務情報
    Transocean Ltd. - Strategy, SWOT and Corporate Finance Report Summary Transocean Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • EPI Ingredients:企業の戦略・SWOT・財務分析
    EPI Ingredients - Strategy, SWOT and Corporate Finance Report Summary EPI Ingredients - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Dentsply Sirona Inc (XRAY):医療機器:M&Aディール及び事業提携情報
    Summary Dentsply Sirona Inc (Dentsply Sirona) formerly Dentsply International Inc, is a medical device company that designs, develops, manufactures and markets a wide range of products for the dental market. It provides dental prosthetics, precious metal dental alloys, dental ceramics, endodontic in …
  • Technogenetics srl:医療機器:M&Aディール及び事業提携情報
    Summary Technogenetics srl (Technogenetics), a subsidiary of Shanghai Kehua Bio-engineering Co Ltd, is an immunodiagnostics and molecular genetics company that offers reagents and instruments in the field of biotechnology and pharmacology. The company provides immunodiagnostics products in the areas …
  • VolitionRX Ltd (VNRX):医療機器:M&Aディール及び事業提携情報
    Summary VolitionRX Ltd (VolitionRX) is a medical equipment provider that develops diagnostics tests for cancer and other conditions. The company develops Nucleosomics, a platform technology used for measurement and identification of nucleosomes in the blood. It develops tools for the diagnosis of va …
  • Nexus AG (NXU):企業の財務・戦略的SWOT分析
    Summary Nexus AG (Nexus) is a healthcare technology company that provides healthcare software solutions. The company provides products such as NEXUS and HIS, a hospital information system; NEXUS and DIS, a special ward and department solutions; and NEXUS and QM, a solution in quality management, amo …
  • Genedata AG-製薬・医療分野:企業M&A・提携分析
    Summary Genedata AG (Genedata) is a healthcare technology company that transforms data into software solutions. The company delivers enterprise solutions for data analytics that streamline research and development workflows and improve research productivity. Its products include genedata biologics, …
  • Seek Limited
    Seek Limited - Strategy, SWOT and Corporate Finance Report Summary Seek Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Bruker Corporation:企業の戦略・SWOT・財務情報
    Bruker Corporation - Strategy, SWOT and Corporate Finance Report Summary Bruker Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Dome Energy AB (DOME):石油・ガス:M&Aディール及び事業提携情報
    Summary Dome Energy AB (Dome Energy), formerly Commodity Quest AB is an oil and gas company that exploits, explores, develops and produces conventional oil and gas reserves. The company explores for onshore oil and gas fields to identify unexploited well locations. It explores and produces oil and g …
  • Menicon Co Ltd (7780)-医療機器分野:企業M&A・提携分析
    Summary Menicon Co Ltd (Menicon) is a medical device company that manufactures, export, import and markets ophthalmic products. The company’s products include soft contact lens, hard contact lens, astigmatic contact lens and bifocal contact lenses, among others. It offers contact lens care products …
  • Volpara Health Technologies Ltd (VHT):医療機器:M&Aディール及び事業提携情報
    Summary Volpara Health Technologies Ltd (Volpara Health) is a medical equipment company that develops and manufactures breast imaging analytics and analysis products that improve clinical decision-making and early detection of breast cancer. The company offers clinically-validated software products …
  • Marksans Pharma Ltd (MARKSANS)-製薬・医療分野:企業M&A・提携分析
    Summary Marksans Pharma Ltd (Marksans Pharma) is a pharmaceutical company that develops, manufactures and markets branded formulations and generic products. The company offers contract research and manufacturing services. Its focus therapy segments comprise antibiotics, antidiabetic, anti-inflammato …
  • Dan Hotels Corporation Ltd:戦略・SWOT・企業財務分析
    Dan Hotels Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Dan Hotels Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • The Norinchukin Bank:企業の戦略・SWOT・財務分析
    The Norinchukin Bank - Strategy, SWOT and Corporate Finance Report Summary The Norinchukin Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sierra Oncology Inc (SRRA):製薬・医療:M&Aディール及び事業提携情報
    Summary Sierra Oncology Inc (Sierra Oncology), formerly ProNAi Therapeutics Inc is a clinical stage drug development company that develops and commercializes DNA damage response therapeutics for the treatment of cancer. The company’s product candidate includes SRA737, an orally bioavailable small mo …
  • Cyclacel Pharmaceuticals Inc (CYCC):企業の財務・戦略的SWOT分析
    Cyclacel Pharmaceuticals Inc (CYCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Quanta Computer Inc (2382):企業の財務・戦略的SWOT分析
    Quanta Computer Inc (2382) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Loews Corp:企業の戦略・SWOT・財務情報
    Loews Corp - Strategy, SWOT and Corporate Finance Report Summary Loews Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆